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Studies on the effect of various antiepileptic drugs on serum lipids show 
contradictory results. We aimed to find the effect of Phenobarbital and Sodium 
Valproate monotherapy on serum lipid profile and liver function tests in epileptic 
children.
Materials & Methods
This cohort study was conducted in Amirkola Children Hospital. One hundred 
and ten children with epilepsy were included in this study. Children with 
hepatic or renal disease, those receiving medications which could alter liver 
function tests or serum lipid profile were excluded from the study. Patients 
were allocated into two groups. The first group, including 63 patients, received 
Phenobarbital and the second group, including 47 patients, received Sodium 
Valproate, both in divided doses. A venous blood sample was collected after 
overnight fasting to evaluate serum triglyceride, total cholesterol, LDL, HDL, 
and liver function tests. Data was analyzed with SPSS version 17.   
Results
In children receiving Phenobarbital, total cholesterol, LDL, HDL, ALP, SGOT and 
SGPT increased significantly after treatment, but TG level showed no significant 
changes. In children receiving Sodium Valproate, HDL, ALP, SGOT, SGPT 
significantly increased after treatment but there were no statistically significant 
changes in total cholesterol, LDL and TG. In our study, the plasma levels of LPa 
elevated significantly after treatment with Phenobarbital and Sodium Valproate 
(P Value=0.0001). This increase was more significant in patients receiving 
Sodium Valproate.
Conclusion
Our results suggested a need for monitoring serum total cholesterol, HDL, LDL, 
and TG levels in patients receiving Phenobarbital and Valproic Acid.
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Introduction 
A seizure or convulsion is a paroxysmal time-limited change in motor activity and/
or behavior that results from abnormal electrical activity in the brain. Seizures are 
common during childhood and occur in 5.2-8.1 per 1000 children, and are the most 
common neurologic disorder in children. However, in most cases, this disorder does 
not lead to a specific diagnosis and is mostly a primary disorder of CNS (Central 
Nervous System) which is called Idiopathic Epilepsy (1,2).
Some childhood seizures are provoked by somatic disorders originating from outside 
34 Iran J Child Neurology   Vol4 No3 Nov  2010
EFFECTS OF ANTICONVULSANT DRUGS ON LIPID PROFILE  AND LIVER ENZYMES 
of the brain, such as a high fever, infection, syncope, 
head trauma, hypoxia, toxins, or cardiac arrhythmias. 
Regarding long-time treatment of epileptic patients, 
these treatment protocols may have some side effects. 
Different studies on the effect of various antiepileptic 
drugs on serum lipid profile have reported contradictory 
results (3,4,5).
The aim of this study was to find the effect of Phenobarbital 
and Valproic Acid monotherapy on serum lipid profile 
and liver function tests in epileptic children.
Materials &Methods
This cohort study was conducted in the Department 
of Pediatric Neurology at Amirkola Pediatric Hospital 
between 2007 and 2008 in order to evaluate the effect 
of antiepileptic drugs of Phenobarbital and Sodium 
Valproate on serum lipid profile [TG (Triglyceride), Ch 
(cholesterol), HDL (High Density Lipoprotein), LDL 
(Low Density Lipoprotein), LPa (Lipoprotein a)] and 
liver enzymes [SGOT (Serum Glutamic Oxaloacetic 
Transaminase), and SGPT (Serum Glutamic Pyruvic 
Transaminase)].
One hundred and ten patients with convulsive attacks 
and the diagnosis of epilepsy were included in this study 
but children with hepatic, renal or metabolic diseases, 
a positive past history of status epilepticus, those 
receiving medications which could alter liver function 
tests or serum lipids and a positive family history of 
atherosclerosis were excluded. 
An informed written consent was signed by each subject 
and prior approval of the institutional ethical committee 
was obtained. Patients were allocated into 2 groups based 
on antiepileptic drug treatment. Group A, including 63 
patients, received Phenobarbital (5mg/kg/d) twice a day 
and group B, including 47 patients, received Sodium 
Valproate (20mg/kg/d) twice daily.
A Venous blood sample (5ml) was collected after overnight 
fasting. Serum levels of Alanin AminoTransferase 
(ALT) and Aspartate AminoTransferase (AST) were 
evaluated through IFCC method, Alkaline Phosphatase 
(ALP) through DGKC method (Deutsche Gesellschaft 
für Klinische Chemie), and serum cholesterol and HDL 
levels through GOD-PAP.
Low-density lipoprotein cholesterol (LDL) was 
calculated using Friedewald formula. The serum level 
of Lipoprotein A was estimated through ELISA method 
before and during treatment (at the 3rd and 6th month)
Data was analyzed using SPSS version 17 and paired 
T-test was applied to compare lipid levels in different 
groups.
Results
Sixty three patients were included in group A but 13 cases 
were excluded during the follow-up period, 3 patients 
for drug resistance and recurrent convulsion, one patient 
for post treatment rashes, one for discontinuing drug and 
8 for not attending in the next sampling. Therefore, we 
had 50 patients in group A with a mean age of 6.22±2.01 
years; 48% were male and 52% were female.
Group B included 47 patients but 11 were excluded 
during the follow-up, one for Sodium Valproate induced 
rashes, 2 for drug resistance, 2 for discontinuing drug and 
6 for not attending in the next sampling. Finally, we had 
36 patients in this group with a mean age of 8.14±3.46 
years; 44.4% were male and 15.6% were female.
Mean changes of cholesterol, HDL, LDL, TG, liver 
enzymes, ALP and LPa in patients treated with 
Phenobarbital and Sodium Valproate are recorded in the 
following graphs and tables.
Based on Graphs 1-6 and tables No 1 and 2, in group 
A, there was a significant difference in all parameters 
except for TG but in group B, a significant difference was 
only seen in LPa (P value=0.0001), HDL (P value=0.049), 
SGOT (P value=0.0001), SGPT (P value=0.0001) and ALP 
(P value=0.049). However, there were no statistically 
significant changes in total cholesterol (P value=0.62), 
LDL (P value=0.148) and TG (P value=0.136). 
Discussion
In our study, the plasma level of LPa showed a significant 
elevation after treatment with Phenobarbital (P 
value=0.0001) and Sodium Valproate (P value=0.0001). 
Moreover, this increase was more significant in patients 
receiving Sodium Valproate (Table 1-2)  
Our results suggested a need for monitoring serum total 
cholesterol, HDL, LDL, and TG levels and perhaps 
prescribing a low cholesterol diet in patients receiving 
antiepileptic drugs.
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0.00010.083<200175.62 ± 35.340161.88 ± 31.702152.90 ± 30.798Ch
0.1720.057<200130.41 ± 48.17129.96 ± 42.23140.14 ± 50.28TG
0.0200.00229-8079.06 ± 22.90577.31 ± 24.53868.81 ± 23.048LDL
0.00010.000129-8067.33 ± 26.09763.52 ± 25.51548.74 ± 17.656HDL
0.00010.007<4135.74 ± 10.99729.36 ± 11.41424.94 ± 10.918SGPT









0.00010.0001<30 mg/dl31.74 ± 10.98427.22 ± 11.49622.70 ± 10.016LPa

















0.6200.778<200152 ± 23.031149.78 ± 19.803148.72 ± 20.084Ch
0.1360.314<200116.38 ± 51.691111.86 ± 46.810106.03 ± 43.312TG
0.1480.78329-8067.68 ± 20.40774.58 ± 24.49276.11 ± 25.255LDL
0.0490.02129-8061.58 ± 13.87360.36 ± 14.33750.86 ± 21.842HDL
0.00010.010<4133.31 ± 8.01424.86 ± 9.62821.47 ± 9.470SGPT









0.00010.002<30 mg/dl36.36 ± 16.69833.85 ± 14.72228.79 ± 12.735LP a
36 Iran J Child Neurology   Vol4 No3 Nov  2010
Sonmez et al found that antiepileptic drugs (Phenobarbital 
and Sodium Valproate) significantly increased the level 
of LPa, which is a major risk factor for atherosclerosis 
and also has variable effects on other lipid parameters. 
This increase was more obvious in patients receiving 
Phenobarbital (1).
Verrotti et al showed that patients treated with 
Phenobarbital and Sodium Valproate revealed significant 
changes in lipid and lipoproteins (2).
Aynaci et al reported that in patients treated with 
Phenobarbital, all the parameters of lipid profile 
significantly increased except for triglycerides and that 
triglyceride reduction was not statistically significant (P 
value<0.25) (6).
Plasma levels of LPa depend on the rate of LPa 
production in liver. Antiepileptic drugs change LPa 
levels by inducing the microsomal enzymes system of 
the liver which is the reason why the level of plasma LPa 
is elevated in patients receiving Phenobarbital.
On the other hand, the biotransformation pathway of 
Sodium Valproate occurs with changes in glucoronic 
acid structure and the beta-oxidation pathway; therefore, 
we do not expect any changes in lipid and LPa levels. 
However, Sonmez et al showed that there was a 
remarkable rise in LPa level in patients receiving Sodium 
Valproate (1-7).
Our results showed that patients receiving Phenobarbital 
and Sodium Valproate experienced a significant increase 
in HDL which was more obvious in the Phenobarbital 
group.
In group A, the serum levels of cholesterol and LDL 
had a significant increase but in group B, there was no 
significant increase in serum cholesterol and LDL levels. 
Also, serum triglyceride level did not change in the two 
groups. 
Franzoni et al reported a significant increase in total 
cholesterol plasma level with Phenobarbital but patients 
receiving Sodium Valproate were very similar to those in 
the control group. The results may be explainable by the 
different biotransformation pathway of these drugs (8).
In our study, there was a significant increase in ALT, 
AST and ALP with Phenobarbital and Sodium Valproate 
which was more significant in patients receiving 
Phenobarbital.
Mendis et al studied 123 unselected patients who were 
on anticonvulsants. The results were compared with 123 
control patients. They found that plasma activities of 
AST and ALP were similar in the two groups but ALT 
was elevated in patients on anticonvulsants (9).
Wall et al reported that ALP was elevated in 29.7% 
and Alanin Transferase in 25.2% of the cases receiving 
anticonvulsant medication (10).
Closed monitoring of serum lipid levels and a long-term 
follow-up of children receiving antiepileptic drugs to 
observe the incidence of ischemic heart disease is needed 
to obtain a clinically significant result (10).
One of the main limitations of our study was the lack of 
long-term follow-up of children on antiepileptic drugs. 
We also recommend long-term serial monitoring of the 
changes of lipid fractions from the beginning until the 
end (or even after the end) of the treatment period.
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Fig 1. Mean serum level of LDL before and after treatment
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Fig 2. Mean serum level of Cholestrol before and after treatment
Fig 3. Mean serum level of SGPT before and after treatment
Fig 4. Mean serum level of SGOT before and after treatment
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Fig 6. Mean serum level of LPa before and after treatment 
